A Small Cohort Omega-3 PUFA Supplement Study: Implications of Stratifying According to Lipid Membrane Incorporation in Cardiac Surgical Patients

Wendy T K Ip, Chanchal Chandramouli, Julian A. Smith, Peter Leslie McLennan, Salvatore Pepe, Lea M Durham Delbridge

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Background Epidemiological studies and randomised clinical trials (RCTs) report disparate findings in relation to omega-3 polyunsaturated fatty acids (n-3 PUFA) benefit for cardiac patients. With RCTs interpretation is potentially confounded by background n-3 PUFA intake. The goal of this pilot, small cohort, pre-surgical supplementation study was to evaluate postoperative atrial fibrillation (AF) and cardiac molecular expression profiles employing two data analysis approaches – by treatment randomisation and by stratification using measured n-3 PUFA. Methods Patients (n = 20) received 3 g/day of fish or placebo oil (FO vs PO) in a double blind randomised protocol prior to elective coronary artery graft and valve surgery. Groups were matched for age, gender, and mean treatment duration (∼20 days). Resected atrial myocardium was sampled for assay of viability metabolic markers, and blood obtained for erythrocyte membrane lipid measurement. Results There was substantial overlap of cell membrane n-3 PUFA content across PO and FO groups, and no group treatment effects on AF incidence or myocardial molecular marker levels were detected. In contrast, data stratification using membrane n-3 PUFA content (at 8% total membrane lipid) achieved significant separation of patients (by n-6:n-3 PUFA ratio), a significant differential cardiac expression of the marker peroxisomal proliferator-activated receptor, but no difference in AF incidence. Conclusions This small n-3 PUFA case study demonstrates that the same cohort may yield differing findings when evaluated using randomisation or stratification approaches based on direct molecular measures in cell membranes.

Original languageEnglish
Pages (from-to)846-855
Number of pages10
JournalHeart Lung and Circulation
Volume26
Issue number8
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • Atrial fibrillation
  • Bax
  • Bcl2
  • Omega-3 polyunsaturated fatty acids (PUFA)
  • Peroxisomal proliferator-activated receptor (PPAR)

Cite this

Ip, Wendy T K ; Chandramouli, Chanchal ; Smith, Julian A. ; McLennan, Peter Leslie ; Pepe, Salvatore ; Delbridge, Lea M Durham. / A Small Cohort Omega-3 PUFA Supplement Study : Implications of Stratifying According to Lipid Membrane Incorporation in Cardiac Surgical Patients. In: Heart Lung and Circulation. 2017 ; Vol. 26, No. 8. pp. 846-855.
@article{abc508afa2e849baa7b4007fe089b918,
title = "A Small Cohort Omega-3 PUFA Supplement Study: Implications of Stratifying According to Lipid Membrane Incorporation in Cardiac Surgical Patients",
abstract = "Background Epidemiological studies and randomised clinical trials (RCTs) report disparate findings in relation to omega-3 polyunsaturated fatty acids (n-3 PUFA) benefit for cardiac patients. With RCTs interpretation is potentially confounded by background n-3 PUFA intake. The goal of this pilot, small cohort, pre-surgical supplementation study was to evaluate postoperative atrial fibrillation (AF) and cardiac molecular expression profiles employing two data analysis approaches – by treatment randomisation and by stratification using measured n-3 PUFA. Methods Patients (n = 20) received 3 g/day of fish or placebo oil (FO vs PO) in a double blind randomised protocol prior to elective coronary artery graft and valve surgery. Groups were matched for age, gender, and mean treatment duration (∼20 days). Resected atrial myocardium was sampled for assay of viability metabolic markers, and blood obtained for erythrocyte membrane lipid measurement. Results There was substantial overlap of cell membrane n-3 PUFA content across PO and FO groups, and no group treatment effects on AF incidence or myocardial molecular marker levels were detected. In contrast, data stratification using membrane n-3 PUFA content (at 8{\%} total membrane lipid) achieved significant separation of patients (by n-6:n-3 PUFA ratio), a significant differential cardiac expression of the marker peroxisomal proliferator-activated receptor, but no difference in AF incidence. Conclusions This small n-3 PUFA case study demonstrates that the same cohort may yield differing findings when evaluated using randomisation or stratification approaches based on direct molecular measures in cell membranes.",
keywords = "Atrial fibrillation, Bax, Bcl2, Omega-3 polyunsaturated fatty acids (PUFA), Peroxisomal proliferator-activated receptor (PPAR)",
author = "Ip, {Wendy T K} and Chanchal Chandramouli and Smith, {Julian A.} and McLennan, {Peter Leslie} and Salvatore Pepe and Delbridge, {Lea M Durham}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.hlc.2016.12.007",
language = "English",
volume = "26",
pages = "846--855",
journal = "Heart Lung and Circulation",
issn = "1443-9506",
publisher = "Elsevier",
number = "8",

}

A Small Cohort Omega-3 PUFA Supplement Study : Implications of Stratifying According to Lipid Membrane Incorporation in Cardiac Surgical Patients. / Ip, Wendy T K; Chandramouli, Chanchal; Smith, Julian A.; McLennan, Peter Leslie; Pepe, Salvatore; Delbridge, Lea M Durham.

In: Heart Lung and Circulation, Vol. 26, No. 8, 01.08.2017, p. 846-855.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A Small Cohort Omega-3 PUFA Supplement Study

T2 - Implications of Stratifying According to Lipid Membrane Incorporation in Cardiac Surgical Patients

AU - Ip, Wendy T K

AU - Chandramouli, Chanchal

AU - Smith, Julian A.

AU - McLennan, Peter Leslie

AU - Pepe, Salvatore

AU - Delbridge, Lea M Durham

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background Epidemiological studies and randomised clinical trials (RCTs) report disparate findings in relation to omega-3 polyunsaturated fatty acids (n-3 PUFA) benefit for cardiac patients. With RCTs interpretation is potentially confounded by background n-3 PUFA intake. The goal of this pilot, small cohort, pre-surgical supplementation study was to evaluate postoperative atrial fibrillation (AF) and cardiac molecular expression profiles employing two data analysis approaches – by treatment randomisation and by stratification using measured n-3 PUFA. Methods Patients (n = 20) received 3 g/day of fish or placebo oil (FO vs PO) in a double blind randomised protocol prior to elective coronary artery graft and valve surgery. Groups were matched for age, gender, and mean treatment duration (∼20 days). Resected atrial myocardium was sampled for assay of viability metabolic markers, and blood obtained for erythrocyte membrane lipid measurement. Results There was substantial overlap of cell membrane n-3 PUFA content across PO and FO groups, and no group treatment effects on AF incidence or myocardial molecular marker levels were detected. In contrast, data stratification using membrane n-3 PUFA content (at 8% total membrane lipid) achieved significant separation of patients (by n-6:n-3 PUFA ratio), a significant differential cardiac expression of the marker peroxisomal proliferator-activated receptor, but no difference in AF incidence. Conclusions This small n-3 PUFA case study demonstrates that the same cohort may yield differing findings when evaluated using randomisation or stratification approaches based on direct molecular measures in cell membranes.

AB - Background Epidemiological studies and randomised clinical trials (RCTs) report disparate findings in relation to omega-3 polyunsaturated fatty acids (n-3 PUFA) benefit for cardiac patients. With RCTs interpretation is potentially confounded by background n-3 PUFA intake. The goal of this pilot, small cohort, pre-surgical supplementation study was to evaluate postoperative atrial fibrillation (AF) and cardiac molecular expression profiles employing two data analysis approaches – by treatment randomisation and by stratification using measured n-3 PUFA. Methods Patients (n = 20) received 3 g/day of fish or placebo oil (FO vs PO) in a double blind randomised protocol prior to elective coronary artery graft and valve surgery. Groups were matched for age, gender, and mean treatment duration (∼20 days). Resected atrial myocardium was sampled for assay of viability metabolic markers, and blood obtained for erythrocyte membrane lipid measurement. Results There was substantial overlap of cell membrane n-3 PUFA content across PO and FO groups, and no group treatment effects on AF incidence or myocardial molecular marker levels were detected. In contrast, data stratification using membrane n-3 PUFA content (at 8% total membrane lipid) achieved significant separation of patients (by n-6:n-3 PUFA ratio), a significant differential cardiac expression of the marker peroxisomal proliferator-activated receptor, but no difference in AF incidence. Conclusions This small n-3 PUFA case study demonstrates that the same cohort may yield differing findings when evaluated using randomisation or stratification approaches based on direct molecular measures in cell membranes.

KW - Atrial fibrillation

KW - Bax

KW - Bcl2

KW - Omega-3 polyunsaturated fatty acids (PUFA)

KW - Peroxisomal proliferator-activated receptor (PPAR)

UR - http://www.scopus.com/inward/record.url?scp=85013380430&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2016.12.007

DO - 10.1016/j.hlc.2016.12.007

M3 - Article

AN - SCOPUS:85013380430

VL - 26

SP - 846

EP - 855

JO - Heart Lung and Circulation

JF - Heart Lung and Circulation

SN - 1443-9506

IS - 8

ER -